Niels Andreasen

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers
    Khalid Iqbal
    New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY 10314, USA
    Ann Neurol 58:748-57. 2005
  2. ncbi CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42
    Niels Andreasen
    Karolinska Institute NEUROTEC, Neurotec, Huddinge University Hospital, Sweden
    World J Biol Psychiatry 4:147-55. 2003
  3. ncbi Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment
    Niels Andreasen
    Neurotec, Department of Geriatric Medicine, B84, Huddinge University Hospital, Stockholm, Sweden
    Acta Neurol Scand Suppl 179:47-51. 2003
  4. ncbi CSF biomarkers for mild cognitive impairment and early Alzheimer's disease
    Niels Andreasen
    Karolinska Institutet, Department of Neurotec, Section of Geriatric Medicine, M51, Karolinska University Hospital, Huddinge, SE 141 86 Stockholm, Sweden
    Clin Neurol Neurosurg 107:165-73. 2005
  5. doi Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo
    Taher Darreh-Shori
    Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden
    Neurobiol Aging 32:2320.e15-32. 2011
  6. ncbi Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain
    Mia E L Blomqvist
    Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden
    Neurobiol Aging 26:795-802. 2005
  7. ncbi Determinants of costs of care for patients with Alzheimer's disease
    Linus Jönsson
    Division of Geriatric Epidemiology, The Neurotec Department, Karolinska Institutet, Stockholm, Sweden
    Int J Geriatr Psychiatry 21:449-59. 2006
  8. ncbi Increasing CSF phospho-tau levels during cognitive decline and progression to dementia
    Christin Andersson
    Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, NOVUM Karolinska University Hospital Huddinge, S 141 86 Stockholm, Sweden
    Neurobiol Aging 29:1466-73. 2008
  9. doi Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease
    Maria Eriksdotter-Jonhagen
    Departments of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Stockholm, Sweden maria eriksdotter jonhagen ki se
    Dement Geriatr Cogn Disord 33:18-28. 2012
  10. ncbi Practical lessons from amyloid immunotherapy trials in Alzheimer disease
    Alina Solomon
    Aging Research Center ARC, Department of Neurobiology, Care Sciences and Society Karolinska Institutet, Stockholm, Sweden
    Curr Alzheimer Res 9:1126-34. 2012

Detail Information

Publications53

  1. ncbi Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers
    Khalid Iqbal
    New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY 10314, USA
    Ann Neurol 58:748-57. 2005
    ..These subgroups, which can be identified by CSF analysis, might benefit differently from different therapeutic drugs...
  2. ncbi CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42
    Niels Andreasen
    Karolinska Institute NEUROTEC, Neurotec, Huddinge University Hospital, Sweden
    World J Biol Psychiatry 4:147-55. 2003
    ..We stress that the CSF markers should be combined with the clinical information and brain-imaging techniques...
  3. ncbi Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment
    Niels Andreasen
    Neurotec, Department of Geriatric Medicine, B84, Huddinge University Hospital, Stockholm, Sweden
    Acta Neurol Scand Suppl 179:47-51. 2003
    ..CSF diagnostic markers will be especially important when drugs with potential effects on the progression of AD (e.g. gamma-secretase inhibitors) will reach the clinical phase...
  4. ncbi CSF biomarkers for mild cognitive impairment and early Alzheimer's disease
    Niels Andreasen
    Karolinska Institutet, Department of Neurotec, Section of Geriatric Medicine, M51, Karolinska University Hospital, Huddinge, SE 141 86 Stockholm, Sweden
    Clin Neurol Neurosurg 107:165-73. 2005
    ....
  5. doi Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo
    Taher Darreh-Shori
    Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden
    Neurobiol Aging 32:2320.e15-32. 2011
    ....
  6. ncbi Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain
    Mia E L Blomqvist
    Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden
    Neurobiol Aging 26:795-802. 2005
    ..Results indicate that alleles of IDE contribute to variability in A beta deposition in the AD brain and suggest that this relationship may have relevance for the degree of cognitive dysfunction in AD patients...
  7. ncbi Determinants of costs of care for patients with Alzheimer's disease
    Linus Jönsson
    Division of Geriatric Epidemiology, The Neurotec Department, Karolinska Institutet, Stockholm, Sweden
    Int J Geriatr Psychiatry 21:449-59. 2006
    ..Alzheimer's disease (AD), the most common cause of dementia, is a major cause of disability and care burden in the elderly. This study aims to estimate the costs of formal and informal care and identity determinants of care costs...
  8. ncbi Increasing CSF phospho-tau levels during cognitive decline and progression to dementia
    Christin Andersson
    Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, NOVUM Karolinska University Hospital Huddinge, S 141 86 Stockholm, Sweden
    Neurobiol Aging 29:1466-73. 2008
    ..Little is known about longitudinal changes of cerebrospinal fluid (CSF) biomarkers during cognitive decline in neurodegenerative disease progression...
  9. doi Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease
    Maria Eriksdotter-Jonhagen
    Departments of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Stockholm, Sweden maria eriksdotter jonhagen ki se
    Dement Geriatr Cogn Disord 33:18-28. 2012
    ..Here we report the results of a first-in-man study of encapsulated cell (EC) biodelivery of NGF to the basal forebrain of AD patients with the primary objective to explore safety and tolerability...
  10. ncbi Practical lessons from amyloid immunotherapy trials in Alzheimer disease
    Alina Solomon
    Aging Research Center ARC, Department of Neurobiology, Care Sciences and Society Karolinska Institutet, Stockholm, Sweden
    Curr Alzheimer Res 9:1126-34. 2012
    ..This study investigates practical experiences of staff and participants in immunotherapy RCTs...
  11. doi Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort
    Anders Gustavsson
    i3 Innovus, Klarabergsviadukten 90 Hus D, 111 64, Stockholm, Sweden
    Eur J Health Econ 13:561-8. 2012
    ..The aim is to estimate prediction models for long-term AD progression and subsequently economic outcomes...
  12. doi Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease
    Taher Darreh-Shori
    Division of Alzheimer Neurobiology Center, Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden
    J Alzheimers Dis 28:443-58. 2012
    ..APOE4-dependent outcome of BCHE-K genotype as AD risk factor arises through a differential phenotypic modulation of BuChE. Future pharmacogenetic studies should include assessment of the subjects' true phenotypic display of BuChE...
  13. pmc Dementia management programme in a community setting and the use of psychotropic drugs in the elderly population
    Erik Jedenius
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet Alzheimer Disease Research Centre, Stockholm, Sweden
    Scand J Prim Health Care 29:181-6. 2011
    ..The objective of the present study is to evaluate whether the dementia programme had a secondary effect on the use of psychotropic medication in the elderly population in general...
  14. pmc Ratio of Aβ42/P-tau181p in CSF is associated with aberrant default mode network in AD
    Xiaozhen Li
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Sci Rep 3:1339. 2013
    ..This finding implicates that the brain functional connectivity within DMN is affected by pathological changes at early stage in AD. This may provide a better understanding of AD pathology progression and improve AD diagnosis...
  15. doi The cost of diagnosing dementia in a community setting
    Erik Jedenius
    Alzheimer s Disease Research Centre, Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Int J Geriatr Psychiatry 25:476-82. 2010
    ..Further, in order to establish prerequisites for care and planning it is important to identify the cost of dementia diagnosis. This study aims to evaluate the cost of establishing a dementia diagnosis...
  16. doi Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease
    Ahmadul Kadir
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Sweden
    Ann Neurol 63:621-31. 2008
    ....
  17. ncbi Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease
    Mia E L Blomqvist
    Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden
    Neurogenetics 5:115-9. 2004
    ..Results were consistent between AD and PD, suggesting the presence of equivalent detrimental and protective alleles. These data highlight a genomic region in the proximity of IDE that may contribute to AD and PD in a similar manner...
  18. doi Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
    Bengt Winblad
    Karolinska Institutet Alzheimer Disease Research Centre and Clinical Trial Unit, Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden
    Lancet Neurol 11:597-604. 2012
    ..We aimed to assess the safety and tolerability of CAD106, a novel active Aβ immunotherapy for patients with Alzheimer's disease, designed to induce N-terminal Aβ-specific antibodies without an Aβ-specific T-cell response...
  19. ncbi Amyloid-related biomarkers for Alzheimer's disease
    Niels Andreasen
    Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Sweden
    Curr Med Chem 15:766-71. 2008
    ....
  20. ncbi Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism
    Hagit Katzov
    Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden
    Hum Mutat 23:358-67. 2004
    ..Results indicate that variants of ABCA1 may affect the risk of AD, providing further support for a genetic link between AD and cholesterol metabolism...
  21. ncbi Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease
    Niels Andreasen
    Department of Geriatric Medicine, Neurotec, Karolinska Institutet, Huddinge University Hospital, SE 141 86 Stockholm, Sweden
    Peptides 23:1205-14. 2002
    ..Recent studies suggest that CSF-Abeta42 have a satisfactory performance when used as a diagnostic marker for AD in clinical routine. This paper reviews CSF-Abeta42 as a biomarker for AD...
  22. pmc A Swedish programme for dementia diagnostics in primary healthcare
    Erik Jedenius
    Alzheimer s Disease Research Centre, Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Scand J Prim Health Care 26:235-40. 2008
    ..To meet diagnostic needs of dementia, a new care programme was implemented in the county of Kalmar, Sweden. The objective of the study was to analyse whether the programme could identify and diagnose the estimated number of new cases...
  23. doi The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase
    Taher Darreh-Shori
    Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Sweden
    Neurobiol Aging 32:1236-48. 2011
    ..In conclusion, ApoE ε4 might impart its pathological role through high protein expression and interaction with BuChE, which in turn might modulate central cholinergic activity and Aβ load in the brain...
  24. ncbi Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL
    Linus Jönsson
    Neurotec, Section for Geriatric Epidemiology, Karolinska Institutet, Stockholm, Sweden
    Alzheimer Dis Assoc Disord 20:49-55. 2006
    ..The study shows that the EuroQoL can be used to rate utilities in Alzheimer disease, but there are important differences between patient- and proxy-ratings...
  25. pmc Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
    Niels Andreasen
    Memory Clinic, M51, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, 17176 Stockholm, Sweden
    Int J Alzheimers Dis 2010:638379. 2010
    ..Should the two cases have been included and deteriorated, additional investigations might have led to the erroneous conclusion that therapy-induced meningoencephalitis had occurred...
  26. doi Measurement of Aβ1-42 in cerebrospinal fluid is influenced by matrix effects
    J Randall Slemmon
    Discovery Medicine and Clinical Pharmacology, Bristol Myers Squibb Company, Wallingford, Connecticut, USA
    J Neurochem 120:325-33. 2012
    ..The data also suggested that denaturation and HPLC of CSF may be a useful approach for studies using Aβ1-42 as a pharmacodynamic marker or in other paradigms where measurement of total non-covalently bound Aβ1-42 is required...
  27. ncbi A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule
    Bengt Winblad
    Karolinska Institutet Alzheimer Research Center, Stockholm, Sweden
    Int J Geriatr Psychiatry 22:456-67. 2007
    ..To compare the efficacy, safety and tolerability of a novel rivastigmine transdermal patch with conventional rivastigmine capsules and placebo in patients with Alzheimer's disease (AD)...
  28. ncbi Longitudinal stability of CSF biomarkers in Alzheimer's disease
    Kaj Blennow
    Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Molndal, Sweden
    Neurosci Lett 419:18-22. 2007
    ....
  29. ncbi Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease
    Malin E Andersson
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Int J Mol Med 20:233-9. 2007
    ..018). These findings support earlier indications that genetic variability in the KNS2 gene may play a role during early stages of AD pathogenesis...
  30. ncbi Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers
    Magnus Sjogren
    Institute of Clinical Neuroscience, Goteborg University, SE 431 80, Goteborg, Sweden
    Clin Chim Acta 332:1-10. 2003
    ..It increases if P-tau is added. An increasing number of studies suggest that supplementary use of these CSF markers, preferably in combination, adds to the accuracy of an AD diagnosis...
  31. ncbi Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting
    Asa K Wallin
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 23:150-60. 2007
    ..Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated...
  32. ncbi Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies
    Hugo Vanderstichele
    Innogenetics NV, Industriepark Zwijnaarde 7, 9052 Gent, Belgium
    Clin Chem Lab Med 44:1472-80. 2006
    ..Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult...
  33. ncbi An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid
    Erik Portelius
    Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, University of Goteborg, Sahlgrenska University Hospital, Molndal, Sweden
    Neurosci Lett 409:215-9. 2006
    ..Here, we provide direct evidence that an Abeta fragment signature consisting of Abeta1-16, Abeta1-33, Abeta1-39, and Abeta1-42 in CSF distinguishes sporadic AD patients from non-demented controls with an overall accuracy of 86%...
  34. ncbi Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients
    Annika Olsson
    Institute of Clinical Neuroscience, Experimental Neuroscience Section, Goteborg University, Sahlgrenska University Hospital, Molndal, Sweden
    Exp Neurol 183:74-80. 2003
    ..Neither the levels of CSF-beta-sAPP nor CSF-Abeta(42) differed when comparing ApoE4 allele-positive with allele-negative individuals...
  35. ncbi Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study
    Harald Hampel
    Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Munich, Germany
    Arch Gen Psychiatry 61:95-102. 2004
    ..Different tau phosphoepitopes can be sensitively detected in cerebrospinal fluid (CSF)...
  36. ncbi Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease
    Annica Johansson
    Department of Clinical Neuroscience, Sahlgrenska University Hospital, Goteborg University, Goteborg, Sweden
    Hum Genet 114:581-7. 2004
    ..Our results provide an important independent replication of previous findings, supporting the existence of CYP46A1 sequence variants that contribute to variability in beta-amyloid metabolism...
  37. ncbi Genetic variation in CTNNA3 encoding alpha-3 catenin and Alzheimer's disease
    Mia E L Blomqvist
    Center for Genomics and Bioinformatics, Karolinska Institute, Berzeliusvag 35, S 171 77 Stockholm, Sweden
    Neurosci Lett 358:220-2. 2004
    ..More detailed studies of regional linkage disequilibrium structure around CTNNA3 will likely be required to determine whether sequence variation in this region impacts AD...
  38. ncbi Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease
    Henrik Zetterberg
    Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Goteborg University, S 413 45 Gothenburg, Sweden
    Neurosci Lett 367:194-6. 2004
    ..35; P = 0.020), although this correlation failed to reach significance in the AD group alone (r = -0.38; P = 0.099). Taken together, the data indicate that TGF-beta1 plays a role in the processes that affect amyloid metabolism in AD...
  39. ncbi Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology
    Annika Olsson
    Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Molndal, Sweden
    Clin Chem 51:336-45. 2005
    ....
  40. ncbi Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231
    Katharina Buerger
    Dementia Research Section and Memory Clinic, Alzheimer Memorial Center, Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany
    Arch Neurol 59:1267-72. 2002
    ....
  41. ncbi Towards compendia of negative genetic association studies: an example for Alzheimer disease
    Mia E L Blomqvist
    Center for Genomics and Bioinformatics, Karolinska Institute, Berzeliusvag 35, 171 77 Stockholm, Sweden
    Hum Genet 119:29-37. 2006
    ..By reporting these data we hope to encourage the publication of gene compendia to guide further studies and aid future meta-analyses aimed at resolving the involvement of genes in complex human traits...
  42. ncbi Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms
    A M Nilselid
    Institute of Clinical Neuroscience, The Sahlgrenska Academy at Goteborg University, Sahlgrenska University Hospital, SE 431 80 Molndal, Sweden
    Neurochem Int 48:718-28. 2006
    ..However, the individual clusterin levels overlap between the two groups, and thus cerebrospinal fluid clusterin measurement is not suitable as a biochemical marker in the diagnosis of Alzheimer's disease...
  43. ncbi Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment
    Hugo Vanderstichele
    Innogenetics NV, Gent, Belgium
    Clin Chem 51:1650-60. 2005
    ..We evaluated whether different beta-amyloid(42) (Abeta42) peptides can add further information to the combined use of tau and Abeta1-42 for predicting risk of progression of MCI to AD...
  44. ncbi The cathepsin D rs17571 polymorphism: effects on CSF tau concentrations in Alzheimer disease
    Matthias Riemenschneider
    Neurochemistry and Neurogenetics Laboratory, Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Munich, Germany
    Hum Mutat 27:532-7. 2006
    ..The result may corroborate the implication of the lysosomal system in the pathogenesis of AD and is of particular importance if CSF tau is used as a diagnostic biomarker...
  45. ncbi Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins
    Pia Davidsson
    Department of Clinical Neuroscience, Experimental Neuroscience Section, Goteborg University, Sahlgrenska University Hospital, Molndal, Sweden
    Brain Res Mol Brain Res 109:128-33. 2002
    ....
  46. ncbi Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease
    Javier Saez-Valero
    Instituto de Neurociencias, UMH CSIC, Campus de San Juan, San Juan, Alicante, Spain
    J Neurosci Res 72:132-6. 2003
    ..7 +/- 6.7 arbitrary units; a.u.) and AD (151.4 +/- 3.8 a.u.) compared with control individuals (141.4 +/- 1.2 a.u., P < 0.05). Our results strongly suggest the involvement of reelin signaling in neurodegenerative pathologies...
  47. ncbi Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease
    María Salud García-Ayllón
    Instituto de Neurociencias de Alicante, Universidad Miguel Hernandez CSIC, Sant Joan d Alacant, Spain
    J Neurochem 101:1701-11. 2007
    ..The varying responses of different AChE species to ChE-I treatment suggest different modes of regulation, which may have therapeutic implications...
  48. ncbi Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease
    Maja Puchades
    Unit of Experimental Neuroscience, Department of Clinical Neuroscience, Goteborg University, Sahlgrenska University Hospital Molndal, S 431 80 Molndal, Goteborg, Sweden
    Brain Res Mol Brain Res 118:140-6. 2003
    ..The levels of 37 proteins spots were altered in AD patients. One of the identified proteins, alpha-2-HS glycoprotein, has not previously been linked to AD. Our study shows that several glycoproteins are altered in AD...
  49. ncbi Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease
    Patrick G Kehoe
    Department of Care of the Elderly, The John James Building, Frenchay Hospital, University of Bristol, UK
    Hum Genet 114:478-83. 2004
    ..These results provide an important complement to existing AD risk data, confirming that ACE harbors sequence variants that contribute to aspects of AD pathology...
  50. ncbi Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients
    Pia Davidsson
    Department of Clinical Neuroscience, Experimental Neuroscience Section, Goteborg University, Sahlgrenska University Hospital Molndal, SE 431 80, Sweden
    Neuroreport 13:611-5. 2002
    ..The most prominently altered proteins were the apolipoproteins, especially proapolipoprotein...
  51. ncbi Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-beta 1-42 and plasma apolipoprotein levels
    Hagit Katzov
    Centre for Genomics and Bioinformatics, Karolinska Institute, Berzelius vag 35, 171 77 Stockholm, Sweden
    J Hum Genet 51:171-9. 2006
    ..Our data illuminate a possible genetic link between Abeta and cholesterol metabolism, but also provide an intriguing example of an environmental exposure that may modify a genotype-phenotype relationship...
  52. ncbi Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment
    Katharina Buerger
    Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany
    Neurosci Lett 391:48-50. 2005
    ..Our study indicates that the apoE epsilon4 carrier status should be considered when CSF P-tau(231P) is evaluated as biomarker candidate of AD in MCI subjects...
  53. pmc The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients
    Jin Moo Lee
    Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Chem 54:1617-23. 2008
    ....